Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.

@article{Jabbour2018ImpactOG,
  title={Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.},
  author={Elias J Jabbour and Dinara Makenbaeva and Melissa Lingohr-Smith and Jay Lin},
  journal={American journal of clinical oncology},
  year={2018},
  volume={41 3},
  pages={213-217}
}
OBJECTIVES This study assessed treatment responses and economic consequences of limiting access to the second-generation BCR-ABL1 tyrosine kinase inhibitors (2G-TKI), dasatinib and nilotinib, for treatment of chronic myelogenous leukemia, while taking into account frequencies of genetic mutations that exhibit different sensitivities to the 2G-TKIs… CONTINUE READING